simaomicin alpha

from an actinomycete strain; RN given refers to (7alpha,11beta,14alpha)-(+)-isomer; RN for cpd without isomeric designation not avail 11/90; structure given in first source

Also Known As:

LL D42067 alpha; LL-D42067alpha

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - simaomicin alpha: 3

Experts

1.	Omura, Satoshi: 2 articles (04/2008 - 05/2004)
2.	Furusawa, Toshiaki: 1 article (04/2008)
3.	Ishiyama, Aki: 1 article (04/2008)
4.	Masuma, Rokuro: 1 article (04/2008)
5.	Namatame, Miyuki: 1 article (04/2008)
6.	Nishihara, Aki: 1 article (04/2008)
7.	Otoguro, Kazuhiko: 1 article (04/2008)
8.	Shiomi, Kazuro: 1 article (04/2008)
9.	Takahashi, Yoko: 1 article (04/2008)
10.	Arai, Masayoshi: 1 article (05/2004)

Related Diseases

1.	Neoplasms (Cancer) 05/07/2004 - "These data suggested that simaomicin alpha disrupts the cell cycle G2 checkpoint of cancer cells selectively, leading to sensitization of cancer cells to anti-cancer reagents."
2.	Malaria 04/01/2008 - "As erythrocytic schizogony of Plasmodium correlates with cell cycle events, we investigated the effect of simaomicin alpha on stage development of the malaria parasite Plasmodium falciparum. "
3.	Coccidiosis 09/01/1990 - "Simaomicin alpha demonstrated potent activity against Gram-positive bacteria and was active in vivo against a variety of Eimeria species causing coccidiosis in chickens."

Related Drugs and Biologics

1.	Indicators and Reagents (Reagents)